A drug that boosts bone growth in children with the most common form of dwarfism may also reduce their chances of sudden infant death syndrome, sleep apnea, and needing surgery, according to a new study ..read more

In a retrospective study believed to be one of the largest of its kind, researchers say they have successfully charted the health risks, growth patterns, and medical and surgical outcomes of 1,374 people with the most common form of dwarfism, called achondroplasia, seen over a 60-year period at four academic medical centers, including Johns Hopkins Medicine. The findings, according to the researchers, not only affirm some long-standing views and trends in the care of those with the condition, but also offer a standardized baseline, a blueprint investigators hope will serve to speed diagnosis a ..read more

The US Food and Drug Administration on Friday approved for the first time a drug to improve growth in children with the most common type of dwarfism ..read more

A phase three global clinical trial led by the Murdoch Children's Research Institute (MCRI) has shown a new drug boosts bone growth in children born with achondroplasia, the most common type of dwarfism ..read more

Children with achondroplasia, the most common form of disproportionate short stature, grow taller with trends in improved body proportions after two years of daily vosoritide treatment, a new study analysis finds. Results of the industry-sponsored study will be presented at ENDO 2021, the Endocrine Society's annual meeting ..read more

Sara was born on a rainy Sunday, the first child to her adoring and overwhelmed parents. Her mother's pregnancy had been uneventful, and all their antenatal tests normal ..read more

A groundbreaking drug that helps regulate bone development has boosted growth rates in children with achondroplasia—the most common type of dwarfism—in a global trial led by Melbourne's Murdoch Children's Research Institute ..read more